Sign in

Paying users zone. Data is covered by hidden .

Get 1 month access to Regeneron Pharmaceuticals Inc. for $13.99, or
get full access to entire website for at least 3 months from $49.99.

We accept:

Regeneron Pharmaceuticals Inc. (REGN)

DuPont Analysis: Decomposition of ROE
Quarterly Data

Difficulty: Beginner

Decomposing ROE involves expressing net income divided by shareholders’ equity as the product of component ratios.

Two-Component Disaggregation of ROE
Three-Component Disaggregation of ROE
Five-Component Disaggregation of ROE
Two-Way Decomposition of ROA
Four-Way Decomposition of ROA
Decomposition of Net Profit Margin

Two-Component Disaggregation of ROE

Regeneron Pharmaceuticals Inc., decomposition of ROE (quarterly data)

	ROE	=	ROA	×	Leverage

Jun 30, 2019		=		×
Mar 31, 2019		=		×
Dec 31, 2018		=		×
Sep 30, 2018		=		×
Jun 30, 2018		=		×
Mar 31, 2018		=		×
Dec 31, 2017		=		×
Sep 30, 2017		=		×
Jun 30, 2017		=		×
Mar 31, 2017		=		×
Dec 31, 2016		=		×
Sep 30, 2016		=		×
Jun 30, 2016		=		×
Mar 31, 2016		=		×
Dec 31, 2015		=		×
Sep 30, 2015		=		×
Jun 30, 2015		=		×
Mar 31, 2015		=		×
Dec 31, 2014		=		×
Sep 30, 2014		=		×
Jun 30, 2014		=		×
Mar 31, 2014		=		×

Based on: 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-12), 10-Q (filing date: 2014-11-04), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-08).

The primary reason for the decrease in Return on Equity (ROE) over Q2 2019 is the decrease in profitability measured by Return on Assets (ROA).

Three-Component Disaggregation of ROE

Regeneron Pharmaceuticals Inc., decomposition of ROE (quarterly data)

	ROE	=	Net Profit Margin	×	Asset Turnover	×	Leverage

Jun 30, 2019		=		×		×
Mar 31, 2019		=		×		×
Dec 31, 2018		=		×		×
Sep 30, 2018		=		×		×
Jun 30, 2018		=		×		×
Mar 31, 2018		=		×		×
Dec 31, 2017		=		×		×
Sep 30, 2017		=		×		×
Jun 30, 2017		=		×		×
Mar 31, 2017		=		×		×
Dec 31, 2016		=		×		×
Sep 30, 2016		=		×		×
Jun 30, 2016		=		×		×
Mar 31, 2016		=		×		×
Dec 31, 2015		=		×		×
Sep 30, 2015		=		×		×
Jun 30, 2015		=		×		×
Mar 31, 2015		=		×		×
Dec 31, 2014		=		×		×
Sep 30, 2014		=		×		×
Jun 30, 2014		=		×		×
Mar 31, 2014		=		×		×

Based on: 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-12), 10-Q (filing date: 2014-11-04), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-08).

The primary reason for the decrease in Return on Equity (ROE) over Q2 2019 is the decrease in profitability measured by Net Profit Margin.

Five-Component Disaggregation of ROE

Regeneron Pharmaceuticals Inc., decomposition of ROE (quarterly data)

	ROE	=	Tax Burden	×	Interest Burden	×	EBIT Margin	×	Asset Turnover	×	Leverage

Jun 30, 2019		=		×		×		×		×
Mar 31, 2019		=		×		×		×		×
Dec 31, 2018		=		×		×		×		×
Sep 30, 2018		=		×		×		×		×
Jun 30, 2018		=		×		×		×		×
Mar 31, 2018		=		×		×		×		×
Dec 31, 2017		=		×		×		×		×
Sep 30, 2017		=		×		×		×		×
Jun 30, 2017		=		×		×		×		×
Mar 31, 2017		=		×		×		×		×
Dec 31, 2016		=		×		×		×		×
Sep 30, 2016		=		×		×		×		×
Jun 30, 2016		=		×		×		×		×
Mar 31, 2016		=		×		×		×		×
Dec 31, 2015		=		×		×		×		×
Sep 30, 2015		=		×		×		×		×
Jun 30, 2015		=		×		×		×		×
Mar 31, 2015		=		×		×		×		×
Dec 31, 2014		=		×		×		×		×
Sep 30, 2014		=		×		×		×		×
Jun 30, 2014		=		×		×		×		×
Mar 31, 2014		=		×		×		×		×

Based on: 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-12), 10-Q (filing date: 2014-11-04), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-08).

The primary reason for the decrease in Return on Equity (ROE) over Q2 2019 is the decrease in operating profitability measured by EBIT Margin.

Two-Way Decomposition of ROA

Regeneron Pharmaceuticals Inc., decomposition of ROA (quarterly data)

	ROA	=	Net Profit Margin	×	Asset Turnover

Jun 30, 2019		=		×
Mar 31, 2019		=		×
Dec 31, 2018		=		×
Sep 30, 2018		=		×
Jun 30, 2018		=		×
Mar 31, 2018		=		×
Dec 31, 2017		=		×
Sep 30, 2017		=		×
Jun 30, 2017		=		×
Mar 31, 2017		=		×
Dec 31, 2016		=		×
Sep 30, 2016		=		×
Jun 30, 2016		=		×
Mar 31, 2016		=		×
Dec 31, 2015		=		×
Sep 30, 2015		=		×
Jun 30, 2015		=		×
Mar 31, 2015		=		×
Dec 31, 2014		=		×
Sep 30, 2014		=		×
Jun 30, 2014		=		×
Mar 31, 2014		=		×

Based on: 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-12), 10-Q (filing date: 2014-11-04), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-08).

The primary reason for the decrease in Return on Assets (ROA) over Q2 2019 is the decrease in profitability measured by Net Profit Margin.

Four-Way Decomposition of ROA

Regeneron Pharmaceuticals Inc., decomposition of ROA (quarterly data)

	ROA	=	Tax Burden	×	Interest Burden	×	EBIT Margin	×	Asset Turnover

Jun 30, 2019		=		×		×		×
Mar 31, 2019		=		×		×		×
Dec 31, 2018		=		×		×		×
Sep 30, 2018		=		×		×		×
Jun 30, 2018		=		×		×		×
Mar 31, 2018		=		×		×		×
Dec 31, 2017		=		×		×		×
Sep 30, 2017		=		×		×		×
Jun 30, 2017		=		×		×		×
Mar 31, 2017		=		×		×		×
Dec 31, 2016		=		×		×		×
Sep 30, 2016		=		×		×		×
Jun 30, 2016		=		×		×		×
Mar 31, 2016		=		×		×		×
Dec 31, 2015		=		×		×		×
Sep 30, 2015		=		×		×		×
Jun 30, 2015		=		×		×		×
Mar 31, 2015		=		×		×		×
Dec 31, 2014		=		×		×		×
Sep 30, 2014		=		×		×		×
Jun 30, 2014		=		×		×		×
Mar 31, 2014		=		×		×		×

Based on: 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-12), 10-Q (filing date: 2014-11-04), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-08).

The primary reason for the decrease in Return on Assets (ROA) over Q2 2019 is the decrease in operating profitability measured by EBIT Margin.

Decomposition of Net Profit Margin

Regeneron Pharmaceuticals Inc., decomposition of Net Profit Margin (quarterly data)

	Net Profit Margin	=	Tax Burden	×	Interest Burden	×	EBIT Margin

Jun 30, 2019		=		×		×
Mar 31, 2019		=		×		×
Dec 31, 2018		=		×		×
Sep 30, 2018		=		×		×
Jun 30, 2018		=		×		×
Mar 31, 2018		=		×		×
Dec 31, 2017		=		×		×
Sep 30, 2017		=		×		×
Jun 30, 2017		=		×		×
Mar 31, 2017		=		×		×
Dec 31, 2016		=		×		×
Sep 30, 2016		=		×		×
Jun 30, 2016		=		×		×
Mar 31, 2016		=		×		×
Dec 31, 2015		=		×		×
Sep 30, 2015		=		×		×
Jun 30, 2015		=		×		×
Mar 31, 2015		=		×		×
Dec 31, 2014		=		×		×
Sep 30, 2014		=		×		×
Jun 30, 2014		=		×		×
Mar 31, 2014		=		×		×

Based on: 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-12), 10-Q (filing date: 2014-11-04), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-08).

The primary reason for the decrease in Net Profit Margin over Q2 2019 is the decrease in operating profitability measured by EBIT Margin.

	Regeneron Pharmaceuticals Inc.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

Price of access to Regeneron Pharmaceuticals Inc.^*

1 month

$13.99

* You can pay in USD, CHF, GBP or EUR.

	All companies
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

Prices of access to the entire website^*

3 months

$49.99

6 months

12% off

~~$99.98~~

$87.49

9 months

25% off

~~$149.97~~

$112.49

12 months

37% off

~~$199.96~~

$124.99

* You can pay in USD, CHF, GBP or EUR.